World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
73
Citations
28245
World Ranking
2088
National Ranking
183

Mark S. Cragg publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Mark S. Cragg sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 301 publications — 64th percentile

64% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Mark S. Cragg D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Mark S. Cragg sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 73 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Mark S. Cragg is affiliated with the University of Southampton in the United Kingdom and has contributed extensively to biomedical research, focusing primarily on medicine and immunology. Their publication record spans multiple subfields, including immunology, radiology, oncology, molecular biology, and genetics.

The main fields of study for this researcher are:

  • Medicine
  • Immunology and Microbiology

Subfields where Mark S. Cragg has published include:

  • Immunology
  • Radiology, Nuclear Medicine and Imaging
  • Oncology
  • Molecular Biology
  • Genetics

The research topics frequently covered by Mark S. Cragg encompass:

  • Monoclonal and Polyclonal Antibodies Research
  • Immune Cell Function and Interaction
  • T-cell and B-cell Immunology
  • Immunotherapy and Immune Responses
  • CAR-T cell therapy research
  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment

Recent papers authored or co-authored by Mark S. Cragg include:

  • Reducing affinity as a strategy to boost immunomodulatory antibody agonism, 2023, Nature
  • Replicative senescence dictates the emergence of disease-associated microglia and contributes to Aβ pathology, 2021, Cell Reports
  • Fc-Engineering for Modulated Effector Functions-Improving Antibodies for Cancer Treatment, 2020, Antibodies
  • Signaling through the Inhibitory Fc Receptor FcγRIIB Induces CD8+ T Cell Apoptosis to Limit T Cell Immunity, 2020, Immunity
  • Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma, 2020, Blood Advances

Mark S. Cragg frequently collaborates with several researchers, including:

  • Stephen A. Beers
  • Björn Frendéus
  • Robert Oldham
  • H. T. Claude Chan
  • Tatyana Inzhelevskaya

The primary venues for their publications include:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Blood
  • Blood Advances
  • Frontiers in Immunology
  • Journal for ImmunoTherapy of Cancer

Best Publications

  • Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Daniel J. Klionsky;Kotb Abdelmohsen;Akihisa Abe;Joynal Abedin

  • Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Daniel J. Klionsky;Kotb Abdelmohsen;Akihisa Abe;Joynal Abedin

  • Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

    Jessica L Teeling;Ruth R French;Mark S Cragg;Jeroen van den Brakel

  • Coupled Proliferation and Apoptosis Maintain the Rapid Turnover of Microglia in the Adult Brain

    Katharine Askew;Kaizhen Li;Adrian Olmos-Alonso;Fernando Garcia-Moreno

  • Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

    Mark S Cragg;Suzanne M Morgan;H T Claude Chan;B Paul Morgan

  • Mechanisms of killing by anti-CD20 monoclonal antibodies.

    Martin J. Glennie;Ruth R. French;Mark S. Cragg;Ronald P. Taylor

  • Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents.

    Mark S. Cragg;Martin J. Glennie

  • The biology of CD20 and its potential as a target for mAb therapy.

    Mark S. Cragg;Claire A. Walshe;Andrey O. Ivanov;Martin J. Glennie

  • Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

    Stephen A. Beers;Ruth R. French;H. T. Claude Chan;Sean H. Lim

  • Gefitinib-Induced Killing of NSCLC Cell Lines Expressing Mutant EGFR Requires BIM and Can Be Enhanced by BH3 Mimetics

    Mark S Cragg;Junya Kuroda;Hamsa Puthalakath;David C. S Huang

  • Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic

    Junya Kuroda;Hamsa Puthalakath;Mark S. Cragg;Priscilla N. Kelly;Priscilla N. Kelly

  • Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies

    Waleed Alduaij;Andrei Ivanov;Jamie Honeychurch;Eleanor J Cheadle

  • Anti-CD20 monoclonal antibodies: historical and future perspectives

    Sean H. Lim;Stephen A. Beers;Ruth R. French;Peter W.M. Johnson

  • Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy

    Sean H Lim;Andrew T Vaughan;Margaret Ashton-Key;Emily L Williams

  • Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Daniel J. Klionsky;Kotb Abdelmohsen;Akihisa Abe;Joynal Abedin

  • CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts

    H T Claude Chan;David Hughes;Ruth R French;Alison L Tutt

  • CD20 as a target for therapeutic type I and II monoclonal antibodies.

    Stephen A. Beers;Claude H.T. Chan;Ruth R. French;Mark S. Cragg

  • Replicative senescence dictates the emergence of disease-associated microglia and contributes to Aβ pathology.

    Yanling Hu;Gemma L. Fryatt;Mohammadmersad Ghorbani;Juliane Obst

  • Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody

    Ann L. White;H. T. Claude Chan;Ali Roghanian;Ruth R. French

  • Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics

    Mark S. Cragg;Claire Harris;Claire Harris;Andreas Strasser;Clare L. Scott;Clare L. Scott

  • Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic

    Mark S. Cragg;Elisa S. Jansen;Michele Cook;Claire Harris

Frequent Co-Authors

Martin J. Glennie
Martin J. Glennie University of Southampton
Peter Johnson
Peter Johnson University of Southampton
Graham Packham
Graham Packham University of Southampton
Aymen Al-Shamkhani
Aymen Al-Shamkhani University of Southampton
David Oscier
David Oscier Royal Bournemouth Hospital
Paul A. Townsend
Paul A. Townsend University of Manchester
Freda K. Stevenson
Freda K. Stevenson University of Southampton
J. Sjef Verbeek
J. Sjef Verbeek Leiden University Medical Center
Andreas Strasser
Andreas Strasser Walter and Eliza Hall Institute of Medical Research
Christian Klein
Christian Klein Roche (Switzerland)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare degrees online can open diverse career opportunities. Nursing programs, especially those leading to advanced practice roles, often align well with immunology knowledge and patient care.

Students can find programs tailored to different career stages, from entry-level LPNs to advanced nurse practitioners. The easiest lpn programs to get into offer accessible pathways for those starting in healthcare and looking to build foundational skills quickly.

For advanced degrees, understanding what makes a program manageable is important. Discovering what is the easiest np program can help prospective students select programs that balance rigor with completion feasibility.

Specializing in areas like psychiatric mental health nursing is another growing field. Identifying the best online psychiatric mental health nurse practitioner programs ensures excellent clinical experiences, a critical component for skill development.

Cost-efficiency is key for many working professionals. Exploring cheap psych np programs can provide affordable routes without compromising educational quality.

Best Scientists Citing Mark S. Cragg

Trending Scientists

Recently Published Articles